Epizyme, Inc.
EPZMN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Mar 1, 2026
21dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
Tazemetostat Phase 3 Results Expected
Mar 1, 2026Tazemetostat612
Primary completion for Tazemetostat trial (NCT04224493) in Relapsed/Refractory Follicular Lymphoma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
Tazemetostat
Diffuse Large B-cell Lymphoma (DLBCL)
Prednisolone
B-cell Lymphomas (Phase 1)
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Tazemetostat | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - |
Prednisolone | Phase 2 | B-cell Lymphomas (Phase 1) | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
EPZM News